İnsan çevirisi örneklerinden çeviri yapmayı öğrenmeye çalışıyor.
Profesyonel çevirmenler, işletmeler, web sayfaları ve erişimin serbest olduğu çeviri havuzlarından.
pacienti liečení vildagliptínom hlásili
in a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline hba1c by -1% compared to -1.6% for metformin (titrated to 2 g/ day) statistical non-inferiority was not achieved.
Son Güncelleme: 2011-10-23
Kullanım Sıklığı: 1
Kalite:
Uyarı: Bu hizalama yanlış olabilir..
Böyle düşünüyorsanız lütfen silin.
vek nemá vplyv na inhibíciu dpp-4 vildagliptínom.
dpp-4 inhibition by vildagliptin is not affected by age.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
pohlavie nemá vplyv na inhibíciu dpp-4 vildagliptínom.
dpp-4 inhibition by vildagliptin is not affected by gender.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
Štúdie s vildagliptínom na zvieratách preukázali reprodukčnú toxicitu pri vysokých dávkach.
for vildagliptin studies in animals have shown reproductive toxicity at high doses.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
nie sú klinické skúsenosti s vildagliptínom a metformínom v trojkombinácii s inými antidiabetikami.
there is no clinical experience of vildagliptin and metformin in triple combination with other antidiabetic agents.
Son Güncelleme: 2012-04-12
Kullanım Sıklığı: 2
Kalite:
väčšina udalostí bola mierna čo do závažnosti a zmizla pri pokračujúcej liečbe vildagliptínom.
the majority of events were mild in severity and resolved with ongoing vildagliptin treatment.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
v týchto štúdiách sa po súčasnom podaní s vildagliptínom nepozorovali žiadne klinicky významné farmakokinetické interakcie.
in these studies, no clinically relevant pharmacokinetic interactions were observed after co-administration with vildagliptin.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
pacienti liečení vildagliptínom hlásili významne nižšiu incidenciu gastrointestinálnych nežiaducich reakcií v porovnaní s pacientmi liečenými metformínom.
patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
známy účinok zvýšenej hladiny glp-1 spôsobujúci spomalené vyprázdňovanie žalúdka sa pri liečbe vildagliptínom nepozoruje.
the known effect of increased glp-1 levels delaying gastric emptying is not observed with vildagliptin treatment.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
preukázala sa však bioekvivalencia zomaristu so súbežne podávaným vildagliptínom a metformínom (pozri časť 5.2).
however, bioequivalence of zomarist with co-administered vildagliptin and metformin has been demonstrated (see section 5.2).
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
výsledky klinických skúšaní vykonaných s perorálnymi antidiabetikami pioglitazónom, metformínom a glyburidom v kombinácii s vildagliptínom neukázali žiadne klinicky významné farmakokinetické interakcie u cieľovej populácie.
results from clinical trials conducted with the oral antidiabetics pioglitazone, metformin and glyburide in combination with vildagliptin have shown no clinically relevant pharmacokinetic interactions in the target population.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
klinické skúsenosti u pacientov s funkčnou triedou iii podľa nyha liečených vildagliptínom sú stále obmedzené a výsledky sú nejednoznačné (pozri časť 5.1).
clinical experience in patients with nyha functional class iii treated with vildagliptin is still limited and results are inconclusive (see section 5.1).
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 1
Kalite:
uskutočnila sa metaanalýza nezávisle a prospektívne potvrdených kardiovaskulárnych udalostí z 25 klinických skúšaní fázy iii trvajúcich viac ako 2 roky, ktorá ukázala, že liečba vildagliptínom sa v porovnaní s komparátormi nespájala so zvýšením kardiovaskulárneho rizika.
a meta-analysis of independently and prospectively adjudicated cardiovascular events from 25 phase iii clinical studies of up to more than 2 years duration was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators.
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 1
Kalite:
Štúdie s vildagliptínom a metformínom na zvieratách nepriniesli dôkaz teratogenity, ale preukázali fetotoxické účinky pri dávkach toxických pre samice (pozri časť 5.3).
studies in animals performed with vildagliptin and metformin have not shown evidence of teratogenicity, but foetotoxic effects at maternotoxic doses (see section 5.3).
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 3
Kalite:
okrem toho v kontrolovaných klinických skúšaniach monoterapie vildagliptínom nebola celková incidencia ukončenia účasti pre nežiaduce reakcie vyššia u pacientov liečených vildagliptínom v dávke 100 mg denne (0,3%) ako pri placebe (0,6%) alebo komparátoroch (0,5%).
in addition, in controlled monotherapy trials with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 5
Kalite: